Vaccine Adjuvants research

Vaccine Adjuvants Comprehensive Study by Type (Pathogen, Adjuvant Emulsion, Particulate, Combination, Others), Application (Veterinary Vaccine Adjuvants, Human Vaccine Adjuvants), Route of Administration (Oral, Intradermal, Intranasal, Intramuscular, Subcutaneous), Disease Type (Infectious Disease, Cancer) Players and Region - Global Market Outlook to 2030

Vaccine Adjuvants Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Vaccine Adjuvants
An adjuvant is a substance which is given in the form of vaccine it enhances the ability to protect against infection. Vaccine adjuvants are important in order to activate the inborn immune response, which in turns result in improved adaptive immunity with enhanced activation of T and B cells. Adjuvants in vaccines help in activating the immune system and are used to create stronger immune allowing the antigens—pathogen components in vaccines to induce long-term protective immunity. Increasing geriatric population globally is driving the market for Vaccine Adjuvants.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Vaccine Adjuvants market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

VaxLiant LLC. (United States), Vaxine Pty Ltd (Australia), Aphios Corporation (United States), Viscogel AB (Sweden), Adjuvatis (France), Sergeant Adjuvants (United States), Sigma-Aldrich Co. LLC. (India), CureVac AG (Germany), Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (Fracne), Agenus, Inc. (United States), Novavax, Inc (United States), SPI Pharma, Inc (United States), Invivogen (United States), Avanti Polar Lipids, Inc. (United States), MPV Technologies (United States) and OZ Biosciences (France) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Vaccine Adjuvants market by Type (Pathogen, Adjuvant Emulsion, Particulate, Combination and Others), Application (Veterinary Vaccine Adjuvants and Human Vaccine Adjuvants) and Region.



On the basis of geography, the market of Vaccine Adjuvants has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Vaccine Adjuvants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Type, the sub-segment i.e. Infectious Disease will boost the Vaccine Adjuvants market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of Use of Synthetic Vaccines and Recombinant Subunit and Technological Advancements in Aluminum Hydroxide-Based Adjuvants

Market Growth Drivers:
High Prevalence of Infectious and Zoonotic Diseases, Increasing Focus on Immunization Programs from Various Government Bodies and Increasing Geriatric Population World Widely

Challenges:
Insufficient Knowledge for Scientific Awareness about Adjuvants among Developing Regions and Lack of Effectiveness, Stability, Safety Concerns, or Manufacturability of Adjuvant Vaccine

Restraints:
High Cost of Adjuvant in Vaccine and Stringent Regulatory Environment and Time-Consuming Approvals

Opportunities:
Growing Focus and Support on the Discovery and Development of Vaccine Adjuvants in Developing and Developed Nations

Market Leaders and their expansionary development strategies
In February 2022, Sanofi and GSK intended to submit data from their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.
In April 2022, GSK and SK Bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione following positive Phase III clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant
“According to food and drugs administration, its regulates both preventive and therapeutic vaccines if they are for infectious disease indications. It consists of OVRR that does not regulate therapeutic vaccines for other indications, such as cancer, which are regulated by the FDA

Key Target Audience
Vaccine adjuvants manufacturers and suppliers, Academic research institutes, Biopharmaceutical and biotechnology companies, Research and development (R&D) companies, Business research and consulting service providers, Medical research laboratories and Academic medical centers and universities

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pathogen
  • Adjuvant Emulsion
  • Particulate
  • Combination
  • Others
By Application
  • Veterinary Vaccine Adjuvants
  • Human Vaccine Adjuvants
By Route of Administration
  • Oral
  • Intradermal
  • Intranasal
  • Intramuscular
  • Subcutaneous

By Disease Type
  • Infectious Disease
  • Cancer

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious and Zoonotic Diseases
      • 3.2.2. Increasing Focus on Immunization Programs from Various Government Bodies
      • 3.2.3. Increasing Geriatric Population World Widely
    • 3.3. Market Challenges
      • 3.3.1. Insufficient Knowledge for Scientific Awareness about Adjuvants among Developing Regions
      • 3.3.2. Lack of Effectiveness, Stability, Safety Concerns, or Manufacturability of Adjuvant Vaccine
    • 3.4. Market Trends
      • 3.4.1. Adoption of Use of Synthetic Vaccines and Recombinant Subunit
      • 3.4.2. Technological Advancements in Aluminum Hydroxide-Based Adjuvants
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vaccine Adjuvants, by Type, Application, Route of Administration, Disease Type and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Vaccine Adjuvants (Value)
      • 5.2.1. Global Vaccine Adjuvants by: Type (Value)
        • 5.2.1.1. Pathogen
        • 5.2.1.2. Adjuvant Emulsion
        • 5.2.1.3. Particulate
        • 5.2.1.4. Combination
        • 5.2.1.5. Others
      • 5.2.2. Global Vaccine Adjuvants by: Application (Value)
        • 5.2.2.1. Veterinary Vaccine Adjuvants
        • 5.2.2.2. Human Vaccine Adjuvants
      • 5.2.3. Global Vaccine Adjuvants by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intradermal
        • 5.2.3.3. Intranasal
        • 5.2.3.4. Intramuscular
        • 5.2.3.5. Subcutaneous
      • 5.2.4. Global Vaccine Adjuvants by: Disease Type (Value)
        • 5.2.4.1. Infectious Disease
        • 5.2.4.2. Cancer
      • 5.2.5. Global Vaccine Adjuvants Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Vaccine Adjuvants (Volume)
      • 5.3.1. Global Vaccine Adjuvants by: Type (Volume)
        • 5.3.1.1. Pathogen
        • 5.3.1.2. Adjuvant Emulsion
        • 5.3.1.3. Particulate
        • 5.3.1.4. Combination
        • 5.3.1.5. Others
      • 5.3.2. Global Vaccine Adjuvants by: Application (Volume)
        • 5.3.2.1. Veterinary Vaccine Adjuvants
        • 5.3.2.2. Human Vaccine Adjuvants
      • 5.3.3. Global Vaccine Adjuvants by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Intradermal
        • 5.3.3.3. Intranasal
        • 5.3.3.4. Intramuscular
        • 5.3.3.5. Subcutaneous
      • 5.3.4. Global Vaccine Adjuvants by: Disease Type (Volume)
        • 5.3.4.1. Infectious Disease
        • 5.3.4.2. Cancer
      • 5.3.5. Global Vaccine Adjuvants Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Vaccine Adjuvants (Price)
      • 5.4.1. Global Vaccine Adjuvants by: Type (Price)
  • 6. Vaccine Adjuvants: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. VaxLiant LLC. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Vaxine Pty Ltd (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aphios Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Viscogel AB (Sweden)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Adjuvatis (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sergeant Adjuvants (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sigma-Aldrich Co. LLC. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CureVac AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Brenntag Biosector (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CSL Limited (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. SEPPIC (Fracne)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Agenus, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Novavax, Inc (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. SPI Pharma, Inc (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Invivogen (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Avanti Polar Lipids, Inc. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. MPV Technologies (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. OZ Biosciences (France)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Vaccine Adjuvants Sale, by Type, Application, Route of Administration, Disease Type and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Vaccine Adjuvants (Value)
      • 7.2.1. Global Vaccine Adjuvants by: Type (Value)
        • 7.2.1.1. Pathogen
        • 7.2.1.2. Adjuvant Emulsion
        • 7.2.1.3. Particulate
        • 7.2.1.4. Combination
        • 7.2.1.5. Others
      • 7.2.2. Global Vaccine Adjuvants by: Application (Value)
        • 7.2.2.1. Veterinary Vaccine Adjuvants
        • 7.2.2.2. Human Vaccine Adjuvants
      • 7.2.3. Global Vaccine Adjuvants by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intradermal
        • 7.2.3.3. Intranasal
        • 7.2.3.4. Intramuscular
        • 7.2.3.5. Subcutaneous
      • 7.2.4. Global Vaccine Adjuvants by: Disease Type (Value)
        • 7.2.4.1. Infectious Disease
        • 7.2.4.2. Cancer
      • 7.2.5. Global Vaccine Adjuvants Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Vaccine Adjuvants (Volume)
      • 7.3.1. Global Vaccine Adjuvants by: Type (Volume)
        • 7.3.1.1. Pathogen
        • 7.3.1.2. Adjuvant Emulsion
        • 7.3.1.3. Particulate
        • 7.3.1.4. Combination
        • 7.3.1.5. Others
      • 7.3.2. Global Vaccine Adjuvants by: Application (Volume)
        • 7.3.2.1. Veterinary Vaccine Adjuvants
        • 7.3.2.2. Human Vaccine Adjuvants
      • 7.3.3. Global Vaccine Adjuvants by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Intradermal
        • 7.3.3.3. Intranasal
        • 7.3.3.4. Intramuscular
        • 7.3.3.5. Subcutaneous
      • 7.3.4. Global Vaccine Adjuvants by: Disease Type (Volume)
        • 7.3.4.1. Infectious Disease
        • 7.3.4.2. Cancer
      • 7.3.5. Global Vaccine Adjuvants Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Vaccine Adjuvants (Price)
      • 7.4.1. Global Vaccine Adjuvants by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vaccine Adjuvants: by Type(USD Million)
  • Table 2. Vaccine Adjuvants Pathogen , by Region USD Million (2018-2023)
  • Table 3. Vaccine Adjuvants Adjuvant Emulsion , by Region USD Million (2018-2023)
  • Table 4. Vaccine Adjuvants Particulate , by Region USD Million (2018-2023)
  • Table 5. Vaccine Adjuvants Combination , by Region USD Million (2018-2023)
  • Table 6. Vaccine Adjuvants Others , by Region USD Million (2018-2023)
  • Table 7. Vaccine Adjuvants: by Application(USD Million)
  • Table 8. Vaccine Adjuvants Veterinary Vaccine Adjuvants , by Region USD Million (2018-2023)
  • Table 9. Vaccine Adjuvants Human Vaccine Adjuvants , by Region USD Million (2018-2023)
  • Table 10. Vaccine Adjuvants: by Route of Administration(USD Million)
  • Table 11. Vaccine Adjuvants Oral , by Region USD Million (2018-2023)
  • Table 12. Vaccine Adjuvants Intradermal , by Region USD Million (2018-2023)
  • Table 13. Vaccine Adjuvants Intranasal , by Region USD Million (2018-2023)
  • Table 14. Vaccine Adjuvants Intramuscular , by Region USD Million (2018-2023)
  • Table 15. Vaccine Adjuvants Subcutaneous , by Region USD Million (2018-2023)
  • Table 16. Vaccine Adjuvants: by Disease Type(USD Million)
  • Table 17. Vaccine Adjuvants Infectious Disease , by Region USD Million (2018-2023)
  • Table 18. Vaccine Adjuvants Cancer , by Region USD Million (2018-2023)
  • Table 19. South America Vaccine Adjuvants, by Country USD Million (2018-2023)
  • Table 20. South America Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 21. South America Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 22. South America Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 23. South America Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 24. Brazil Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 25. Brazil Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 26. Brazil Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 27. Brazil Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 28. Argentina Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 29. Argentina Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 30. Argentina Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 31. Argentina Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 32. Rest of South America Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 35. Rest of South America Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 36. Asia Pacific Vaccine Adjuvants, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 40. Asia Pacific Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 41. China Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 42. China Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 43. China Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 44. China Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 45. Japan Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 46. Japan Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 47. Japan Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 48. Japan Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 49. India Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 50. India Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 51. India Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 52. India Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 53. South Korea Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 54. South Korea Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 55. South Korea Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 56. South Korea Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 57. Taiwan Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 58. Taiwan Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 59. Taiwan Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 60. Taiwan Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 61. Australia Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 62. Australia Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 63. Australia Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 64. Australia Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 69. Europe Vaccine Adjuvants, by Country USD Million (2018-2023)
  • Table 70. Europe Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 71. Europe Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 72. Europe Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 73. Europe Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 74. Germany Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 75. Germany Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 76. Germany Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 77. Germany Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 78. France Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 79. France Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 80. France Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 81. France Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 82. Italy Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 83. Italy Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 84. Italy Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 85. Italy Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 86. United Kingdom Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 89. United Kingdom Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 90. Netherlands Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 91. Netherlands Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 92. Netherlands Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 93. Netherlands Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 94. Rest of Europe Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 97. Rest of Europe Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 98. MEA Vaccine Adjuvants, by Country USD Million (2018-2023)
  • Table 99. MEA Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 100. MEA Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 101. MEA Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 102. MEA Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 103. Middle East Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 104. Middle East Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 105. Middle East Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 106. Middle East Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 107. Africa Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 108. Africa Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 109. Africa Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 110. Africa Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 111. North America Vaccine Adjuvants, by Country USD Million (2018-2023)
  • Table 112. North America Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 113. North America Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 114. North America Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 115. North America Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 116. United States Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 117. United States Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 118. United States Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 119. United States Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 120. Canada Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 121. Canada Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 122. Canada Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 123. Canada Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 124. Mexico Vaccine Adjuvants, by Type USD Million (2018-2023)
  • Table 125. Mexico Vaccine Adjuvants, by Application USD Million (2018-2023)
  • Table 126. Mexico Vaccine Adjuvants, by Route of Administration USD Million (2018-2023)
  • Table 127. Mexico Vaccine Adjuvants, by Disease Type USD Million (2018-2023)
  • Table 128. Vaccine Adjuvants Sales: by Type(Unit)
  • Table 129. Vaccine Adjuvants Sales Pathogen , by Region Unit (2018-2023)
  • Table 130. Vaccine Adjuvants Sales Adjuvant Emulsion , by Region Unit (2018-2023)
  • Table 131. Vaccine Adjuvants Sales Particulate , by Region Unit (2018-2023)
  • Table 132. Vaccine Adjuvants Sales Combination , by Region Unit (2018-2023)
  • Table 133. Vaccine Adjuvants Sales Others , by Region Unit (2018-2023)
  • Table 134. Vaccine Adjuvants Sales: by Application(Unit)
  • Table 135. Vaccine Adjuvants Sales Veterinary Vaccine Adjuvants , by Region Unit (2018-2023)
  • Table 136. Vaccine Adjuvants Sales Human Vaccine Adjuvants , by Region Unit (2018-2023)
  • Table 137. Vaccine Adjuvants Sales: by Route of Administration(Unit)
  • Table 138. Vaccine Adjuvants Sales Oral , by Region Unit (2018-2023)
  • Table 139. Vaccine Adjuvants Sales Intradermal , by Region Unit (2018-2023)
  • Table 140. Vaccine Adjuvants Sales Intranasal , by Region Unit (2018-2023)
  • Table 141. Vaccine Adjuvants Sales Intramuscular , by Region Unit (2018-2023)
  • Table 142. Vaccine Adjuvants Sales Subcutaneous , by Region Unit (2018-2023)
  • Table 143. Vaccine Adjuvants Sales: by Disease Type(Unit)
  • Table 144. Vaccine Adjuvants Sales Infectious Disease , by Region Unit (2018-2023)
  • Table 145. Vaccine Adjuvants Sales Cancer , by Region Unit (2018-2023)
  • Table 146. South America Vaccine Adjuvants Sales, by Country Unit (2018-2023)
  • Table 147. South America Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 148. South America Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 149. South America Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 150. South America Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 151. Brazil Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 152. Brazil Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 153. Brazil Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 154. Brazil Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 155. Argentina Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 156. Argentina Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 157. Argentina Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 158. Argentina Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 159. Rest of South America Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 160. Rest of South America Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 161. Rest of South America Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 162. Rest of South America Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 163. Asia Pacific Vaccine Adjuvants Sales, by Country Unit (2018-2023)
  • Table 164. Asia Pacific Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 165. Asia Pacific Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 166. Asia Pacific Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 167. Asia Pacific Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 168. China Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 169. China Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 170. China Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 171. China Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 172. Japan Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 173. Japan Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 174. Japan Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 175. Japan Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 176. India Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 177. India Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 178. India Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 179. India Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 180. South Korea Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 181. South Korea Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 182. South Korea Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 183. South Korea Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 184. Taiwan Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 185. Taiwan Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 186. Taiwan Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 187. Taiwan Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 188. Australia Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 189. Australia Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 190. Australia Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 191. Australia Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 192. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 193. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 194. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 195. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 196. Europe Vaccine Adjuvants Sales, by Country Unit (2018-2023)
  • Table 197. Europe Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 198. Europe Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 199. Europe Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 200. Europe Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 201. Germany Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 202. Germany Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 203. Germany Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 204. Germany Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 205. France Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 206. France Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 207. France Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 208. France Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 209. Italy Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 210. Italy Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 211. Italy Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 212. Italy Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 213. United Kingdom Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 214. United Kingdom Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 215. United Kingdom Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 216. United Kingdom Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 217. Netherlands Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 218. Netherlands Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 219. Netherlands Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 220. Netherlands Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 221. Rest of Europe Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 222. Rest of Europe Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 223. Rest of Europe Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 224. Rest of Europe Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 225. MEA Vaccine Adjuvants Sales, by Country Unit (2018-2023)
  • Table 226. MEA Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 227. MEA Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 228. MEA Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 229. MEA Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 230. Middle East Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 231. Middle East Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 232. Middle East Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 233. Middle East Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 234. Africa Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 235. Africa Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 236. Africa Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 237. Africa Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 238. North America Vaccine Adjuvants Sales, by Country Unit (2018-2023)
  • Table 239. North America Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 240. North America Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 241. North America Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 242. North America Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 243. United States Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 244. United States Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 245. United States Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 246. United States Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 247. Canada Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 248. Canada Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 249. Canada Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 250. Canada Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 251. Mexico Vaccine Adjuvants Sales, by Type Unit (2018-2023)
  • Table 252. Mexico Vaccine Adjuvants Sales, by Application Unit (2018-2023)
  • Table 253. Mexico Vaccine Adjuvants Sales, by Route of Administration Unit (2018-2023)
  • Table 254. Mexico Vaccine Adjuvants Sales, by Disease Type Unit (2018-2023)
  • Table 255. Vaccine Adjuvants: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Vaccine Adjuvants: by Type(USD Million)
  • Table 275. Vaccine Adjuvants Pathogen , by Region USD Million (2025-2030)
  • Table 276. Vaccine Adjuvants Adjuvant Emulsion , by Region USD Million (2025-2030)
  • Table 277. Vaccine Adjuvants Particulate , by Region USD Million (2025-2030)
  • Table 278. Vaccine Adjuvants Combination , by Region USD Million (2025-2030)
  • Table 279. Vaccine Adjuvants Others , by Region USD Million (2025-2030)
  • Table 280. Vaccine Adjuvants: by Application(USD Million)
  • Table 281. Vaccine Adjuvants Veterinary Vaccine Adjuvants , by Region USD Million (2025-2030)
  • Table 282. Vaccine Adjuvants Human Vaccine Adjuvants , by Region USD Million (2025-2030)
  • Table 283. Vaccine Adjuvants: by Route of Administration(USD Million)
  • Table 284. Vaccine Adjuvants Oral , by Region USD Million (2025-2030)
  • Table 285. Vaccine Adjuvants Intradermal , by Region USD Million (2025-2030)
  • Table 286. Vaccine Adjuvants Intranasal , by Region USD Million (2025-2030)
  • Table 287. Vaccine Adjuvants Intramuscular , by Region USD Million (2025-2030)
  • Table 288. Vaccine Adjuvants Subcutaneous , by Region USD Million (2025-2030)
  • Table 289. Vaccine Adjuvants: by Disease Type(USD Million)
  • Table 290. Vaccine Adjuvants Infectious Disease , by Region USD Million (2025-2030)
  • Table 291. Vaccine Adjuvants Cancer , by Region USD Million (2025-2030)
  • Table 292. South America Vaccine Adjuvants, by Country USD Million (2025-2030)
  • Table 293. South America Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 294. South America Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 295. South America Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 296. South America Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 297. Brazil Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 298. Brazil Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 299. Brazil Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 300. Brazil Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 301. Argentina Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 302. Argentina Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 303. Argentina Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 304. Argentina Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 305. Rest of South America Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 306. Rest of South America Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 307. Rest of South America Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 308. Rest of South America Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 309. Asia Pacific Vaccine Adjuvants, by Country USD Million (2025-2030)
  • Table 310. Asia Pacific Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 311. Asia Pacific Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 312. Asia Pacific Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 313. Asia Pacific Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 314. China Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 315. China Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 316. China Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 317. China Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 318. Japan Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 319. Japan Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 320. Japan Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 321. Japan Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 322. India Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 323. India Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 324. India Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 325. India Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 326. South Korea Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 327. South Korea Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 328. South Korea Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 329. South Korea Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 330. Taiwan Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 331. Taiwan Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 332. Taiwan Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 333. Taiwan Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 334. Australia Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 335. Australia Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 336. Australia Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 337. Australia Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 338. Rest of Asia-Pacific Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 342. Europe Vaccine Adjuvants, by Country USD Million (2025-2030)
  • Table 343. Europe Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 344. Europe Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 345. Europe Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 346. Europe Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 347. Germany Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 348. Germany Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 349. Germany Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 350. Germany Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 351. France Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 352. France Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 353. France Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 354. France Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 355. Italy Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 356. Italy Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 357. Italy Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 358. Italy Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 359. United Kingdom Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 360. United Kingdom Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 361. United Kingdom Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 362. United Kingdom Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 363. Netherlands Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 364. Netherlands Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 365. Netherlands Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 366. Netherlands Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 367. Rest of Europe Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 368. Rest of Europe Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 369. Rest of Europe Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 370. Rest of Europe Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 371. MEA Vaccine Adjuvants, by Country USD Million (2025-2030)
  • Table 372. MEA Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 373. MEA Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 374. MEA Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 375. MEA Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 376. Middle East Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 377. Middle East Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 378. Middle East Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 379. Middle East Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 380. Africa Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 381. Africa Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 382. Africa Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 383. Africa Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 384. North America Vaccine Adjuvants, by Country USD Million (2025-2030)
  • Table 385. North America Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 386. North America Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 387. North America Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 388. North America Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 389. United States Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 390. United States Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 391. United States Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 392. United States Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 393. Canada Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 394. Canada Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 395. Canada Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 396. Canada Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 397. Mexico Vaccine Adjuvants, by Type USD Million (2025-2030)
  • Table 398. Mexico Vaccine Adjuvants, by Application USD Million (2025-2030)
  • Table 399. Mexico Vaccine Adjuvants, by Route of Administration USD Million (2025-2030)
  • Table 400. Mexico Vaccine Adjuvants, by Disease Type USD Million (2025-2030)
  • Table 401. Vaccine Adjuvants Sales: by Type(Unit)
  • Table 402. Vaccine Adjuvants Sales Pathogen , by Region Unit (2025-2030)
  • Table 403. Vaccine Adjuvants Sales Adjuvant Emulsion , by Region Unit (2025-2030)
  • Table 404. Vaccine Adjuvants Sales Particulate , by Region Unit (2025-2030)
  • Table 405. Vaccine Adjuvants Sales Combination , by Region Unit (2025-2030)
  • Table 406. Vaccine Adjuvants Sales Others , by Region Unit (2025-2030)
  • Table 407. Vaccine Adjuvants Sales: by Application(Unit)
  • Table 408. Vaccine Adjuvants Sales Veterinary Vaccine Adjuvants , by Region Unit (2025-2030)
  • Table 409. Vaccine Adjuvants Sales Human Vaccine Adjuvants , by Region Unit (2025-2030)
  • Table 410. Vaccine Adjuvants Sales: by Route of Administration(Unit)
  • Table 411. Vaccine Adjuvants Sales Oral , by Region Unit (2025-2030)
  • Table 412. Vaccine Adjuvants Sales Intradermal , by Region Unit (2025-2030)
  • Table 413. Vaccine Adjuvants Sales Intranasal , by Region Unit (2025-2030)
  • Table 414. Vaccine Adjuvants Sales Intramuscular , by Region Unit (2025-2030)
  • Table 415. Vaccine Adjuvants Sales Subcutaneous , by Region Unit (2025-2030)
  • Table 416. Vaccine Adjuvants Sales: by Disease Type(Unit)
  • Table 417. Vaccine Adjuvants Sales Infectious Disease , by Region Unit (2025-2030)
  • Table 418. Vaccine Adjuvants Sales Cancer , by Region Unit (2025-2030)
  • Table 419. South America Vaccine Adjuvants Sales, by Country Unit (2025-2030)
  • Table 420. South America Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 421. South America Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 422. South America Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 423. South America Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 424. Brazil Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 425. Brazil Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 426. Brazil Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 427. Brazil Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 428. Argentina Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 429. Argentina Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 430. Argentina Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 431. Argentina Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 432. Rest of South America Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 433. Rest of South America Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 434. Rest of South America Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 435. Rest of South America Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 436. Asia Pacific Vaccine Adjuvants Sales, by Country Unit (2025-2030)
  • Table 437. Asia Pacific Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 438. Asia Pacific Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 439. Asia Pacific Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 440. Asia Pacific Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 441. China Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 442. China Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 443. China Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 444. China Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 445. Japan Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 446. Japan Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 447. Japan Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 448. Japan Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 449. India Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 450. India Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 451. India Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 452. India Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 453. South Korea Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 454. South Korea Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 455. South Korea Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 456. South Korea Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 457. Taiwan Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 458. Taiwan Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 459. Taiwan Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 460. Taiwan Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 461. Australia Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 462. Australia Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 463. Australia Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 464. Australia Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 465. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 466. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 467. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 468. Rest of Asia-Pacific Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 469. Europe Vaccine Adjuvants Sales, by Country Unit (2025-2030)
  • Table 470. Europe Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 471. Europe Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 472. Europe Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 473. Europe Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 474. Germany Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 475. Germany Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 476. Germany Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 477. Germany Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 478. France Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 479. France Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 480. France Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 481. France Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 482. Italy Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 483. Italy Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 484. Italy Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 485. Italy Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 486. United Kingdom Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 487. United Kingdom Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 488. United Kingdom Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 489. United Kingdom Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 490. Netherlands Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 491. Netherlands Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 492. Netherlands Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 493. Netherlands Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 494. Rest of Europe Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 495. Rest of Europe Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 496. Rest of Europe Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 497. Rest of Europe Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 498. MEA Vaccine Adjuvants Sales, by Country Unit (2025-2030)
  • Table 499. MEA Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 500. MEA Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 501. MEA Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 502. MEA Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 503. Middle East Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 504. Middle East Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 505. Middle East Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 506. Middle East Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 507. Africa Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 508. Africa Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 509. Africa Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 510. Africa Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 511. North America Vaccine Adjuvants Sales, by Country Unit (2025-2030)
  • Table 512. North America Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 513. North America Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 514. North America Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 515. North America Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 516. United States Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 517. United States Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 518. United States Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 519. United States Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 520. Canada Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 521. Canada Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 522. Canada Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 523. Canada Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 524. Mexico Vaccine Adjuvants Sales, by Type Unit (2025-2030)
  • Table 525. Mexico Vaccine Adjuvants Sales, by Application Unit (2025-2030)
  • Table 526. Mexico Vaccine Adjuvants Sales, by Route of Administration Unit (2025-2030)
  • Table 527. Mexico Vaccine Adjuvants Sales, by Disease Type Unit (2025-2030)
  • Table 528. Vaccine Adjuvants: by Type(USD/Units)
  • Table 529. Research Programs/Design for This Report
  • Table 530. Key Data Information from Secondary Sources
  • Table 531. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vaccine Adjuvants: by Type USD Million (2018-2023)
  • Figure 5. Global Vaccine Adjuvants: by Application USD Million (2018-2023)
  • Figure 6. Global Vaccine Adjuvants: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Vaccine Adjuvants: by Disease Type USD Million (2018-2023)
  • Figure 8. South America Vaccine Adjuvants Share (%), by Country
  • Figure 9. Asia Pacific Vaccine Adjuvants Share (%), by Country
  • Figure 10. Europe Vaccine Adjuvants Share (%), by Country
  • Figure 11. MEA Vaccine Adjuvants Share (%), by Country
  • Figure 12. North America Vaccine Adjuvants Share (%), by Country
  • Figure 13. Global Vaccine Adjuvants: by Type Unit (2018-2023)
  • Figure 14. Global Vaccine Adjuvants: by Application Unit (2018-2023)
  • Figure 15. Global Vaccine Adjuvants: by Route of Administration Unit (2018-2023)
  • Figure 16. Global Vaccine Adjuvants: by Disease Type Unit (2018-2023)
  • Figure 17. South America Vaccine Adjuvants Share (%), by Country
  • Figure 18. Asia Pacific Vaccine Adjuvants Share (%), by Country
  • Figure 19. Europe Vaccine Adjuvants Share (%), by Country
  • Figure 20. MEA Vaccine Adjuvants Share (%), by Country
  • Figure 21. North America Vaccine Adjuvants Share (%), by Country
  • Figure 22. Global Vaccine Adjuvants: by Type USD/Units (2018-2023)
  • Figure 23. Global Vaccine Adjuvants share by Players 2023 (%)
  • Figure 24. Global Vaccine Adjuvants share by Players (Top 3) 2023(%)
  • Figure 25. Global Vaccine Adjuvants share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. VaxLiant LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 28. VaxLiant LLC. (United States) Revenue: by Geography 2023
  • Figure 29. Vaxine Pty Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Vaxine Pty Ltd (Australia) Revenue: by Geography 2023
  • Figure 31. Aphios Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Aphios Corporation (United States) Revenue: by Geography 2023
  • Figure 33. Viscogel AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 34. Viscogel AB (Sweden) Revenue: by Geography 2023
  • Figure 35. Adjuvatis (France) Revenue, Net Income and Gross profit
  • Figure 36. Adjuvatis (France) Revenue: by Geography 2023
  • Figure 37. Sergeant Adjuvants (United States) Revenue, Net Income and Gross profit
  • Figure 38. Sergeant Adjuvants (United States) Revenue: by Geography 2023
  • Figure 39. Sigma-Aldrich Co. LLC. (India) Revenue, Net Income and Gross profit
  • Figure 40. Sigma-Aldrich Co. LLC. (India) Revenue: by Geography 2023
  • Figure 41. CureVac AG (Germany) Revenue, Net Income and Gross profit
  • Figure 42. CureVac AG (Germany) Revenue: by Geography 2023
  • Figure 43. Brenntag Biosector (Denmark) Revenue, Net Income and Gross profit
  • Figure 44. Brenntag Biosector (Denmark) Revenue: by Geography 2023
  • Figure 45. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 46. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 47. SEPPIC (Fracne) Revenue, Net Income and Gross profit
  • Figure 48. SEPPIC (Fracne) Revenue: by Geography 2023
  • Figure 49. Agenus, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 50. Agenus, Inc. (United States) Revenue: by Geography 2023
  • Figure 51. Novavax, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 52. Novavax, Inc (United States) Revenue: by Geography 2023
  • Figure 53. SPI Pharma, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 54. SPI Pharma, Inc (United States) Revenue: by Geography 2023
  • Figure 55. Invivogen (United States) Revenue, Net Income and Gross profit
  • Figure 56. Invivogen (United States) Revenue: by Geography 2023
  • Figure 57. Avanti Polar Lipids, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 58. Avanti Polar Lipids, Inc. (United States) Revenue: by Geography 2023
  • Figure 59. MPV Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 60. MPV Technologies (United States) Revenue: by Geography 2023
  • Figure 61. OZ Biosciences (France) Revenue, Net Income and Gross profit
  • Figure 62. OZ Biosciences (France) Revenue: by Geography 2023
  • Figure 63. Global Vaccine Adjuvants: by Type USD Million (2025-2030)
  • Figure 64. Global Vaccine Adjuvants: by Application USD Million (2025-2030)
  • Figure 65. Global Vaccine Adjuvants: by Route of Administration USD Million (2025-2030)
  • Figure 66. Global Vaccine Adjuvants: by Disease Type USD Million (2025-2030)
  • Figure 67. South America Vaccine Adjuvants Share (%), by Country
  • Figure 68. Asia Pacific Vaccine Adjuvants Share (%), by Country
  • Figure 69. Europe Vaccine Adjuvants Share (%), by Country
  • Figure 70. MEA Vaccine Adjuvants Share (%), by Country
  • Figure 71. North America Vaccine Adjuvants Share (%), by Country
  • Figure 72. Global Vaccine Adjuvants: by Type Unit (2025-2030)
  • Figure 73. Global Vaccine Adjuvants: by Application Unit (2025-2030)
  • Figure 74. Global Vaccine Adjuvants: by Route of Administration Unit (2025-2030)
  • Figure 75. Global Vaccine Adjuvants: by Disease Type Unit (2025-2030)
  • Figure 76. South America Vaccine Adjuvants Share (%), by Country
  • Figure 77. Asia Pacific Vaccine Adjuvants Share (%), by Country
  • Figure 78. Europe Vaccine Adjuvants Share (%), by Country
  • Figure 79. MEA Vaccine Adjuvants Share (%), by Country
  • Figure 80. North America Vaccine Adjuvants Share (%), by Country
  • Figure 81. Global Vaccine Adjuvants: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • VaxLiant LLC. (United States)
  • Vaxine Pty Ltd (Australia)
  • Aphios Corporation (United States)
  • Viscogel AB (Sweden)
  • Adjuvatis (France)
  • Sergeant Adjuvants (United States)
  • Sigma-Aldrich Co. LLC. (India)
  • CureVac AG (Germany)
  • Brenntag Biosector (Denmark)
  • CSL Limited (Australia)
  • SEPPIC (Fracne)
  • Agenus, Inc. (United States)
  • Novavax, Inc (United States)
  • SPI Pharma, Inc (United States)
  • Invivogen (United States)
  • Avanti Polar Lipids, Inc. (United States)
  • MPV Technologies (United States)
  • OZ Biosciences (France)
Select User Access Type

Key Highlights of Report


May 2024 208 Pages 51 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Vaccine Adjuvants research Quantitative research analysis
Vaccine Adjuvants research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as VaxLiant LLC. (United States), Vaxine Pty Ltd (Australia), Aphios Corporation (United States), Viscogel AB (Sweden), Adjuvatis (France), Sergeant Adjuvants (United States), Sigma-Aldrich Co. LLC. (India), CureVac AG (Germany), Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (Fracne), Agenus, Inc. (United States), Novavax, Inc (United States), SPI Pharma, Inc (United States), Invivogen (United States), Avanti Polar Lipids, Inc. (United States), MPV Technologies (United States) and OZ Biosciences (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Use of Synthetic Vaccines and Recombinant Subunit " is seen as one of major influencing trends for Vaccine Adjuvants Market during projected period 2023-2030.
The Vaccine Adjuvants market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Vaccine Adjuvants research Report?

Have a Query? Click Here

Other Related Reports

Smart Medical Devices Comprehensive Study by Type (On-Body (Adhesive Patch), Off-Body (Belt Clip), Hand-Held), Application (Oncology, Diabetes, Auto-Immune Disorders, Infectious Diseases, Others), Di...
$ 3750
Pacemaker Devices Comprehensive Study by Type (Single Chamber Pacemaker, Dual Chamber Pacemaker, Biventricular Pacemaker), Application (Arrhythmia, Atrial Fibrillation, Bradycardia, Tachycardia), Tec...
$ 3650
Urology Devices Comprehensive Study by Type (Instruments, Consumables and Accessories), Application (Hospitals, Diagnosis and Treatment Centers, Others), Disease (Kidney Diseases, Cancer and BPH, Pel...
$ 3450
Atherectomy Devices Comprehensive Study by Type (Rotational Atherectomy, Pathway Jetstream PV Atherectomy System, Excimer Laser Atherectomy, Orbital Atherectomy, Silverhawk Plaque Excision System, Ot...
$ 3650
Orthotic Devices Comprehensive Study by Type (Knee Braces and Supports, Ankle Braces and Supports, Upper Extremity Braces and Supports, Spinal Braces and Supports, Foot Insoles), Application (Injurie...
$ 3650
Insufflator Comprehensive Study by Type (Low Flow, Middle Flow, High Flow), Application (Laparoscopy, Bariatric surgery, Heart surgery, Other surgeries), End Users (Hospitals, Clinics, Others) Player...
$ 3500